-Reuters
Baird Maintains Outperform on Axon Enterprise, Raises Price Target to $150
Baird analyst William Power maintains Axon Enterprise (NASDAQ:AXON) with a Outperform and raises the price target from $130 to $150.
Related Posts
Mizuho Maintains Buy on Mobileye Global, Raises Price Target to $40
Mizuho analyst Vijay Rakesh maintains Mobileye Global (NASDAQ:MBLY) with a Buy and raises the price target from $35 to $40.
Here’s How Much $100 Invested In Coterra Energy 20 Years Ago Would Be Worth Today
Coterra Energy (NYSE:CTRA) has outperformed the market over the past 20 years by 21.69% on an annualized basis…
Cosmos Health Actively Exploring Spinoff Of R&D Division Into A Publicly Listed Standalone Biotech Company
Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary nutraceutical brands, manufacturer